Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. 2012

Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
The Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Department of Urology, Glossop Road, Sheffield S10 2JF, UK.

BACKGROUND Silodosin is a new uroselective alpha-blocker with high pharmacological selectivity for the (1A) adrenoceptor. It is an effective and well-tolerated treatment in men with lower urinary tract symptoms (LUTS), due to presumed bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH). The efficacy of silodosin is at least equivalent to existing selective alpha-1 antagonists such as tamsulosin. A beneficial consequence of its high selectivity is improved cardiovascular safety and failure to interact with other therapies such as anti-hypertensives and phosphodiesterase type-5 inhibitors. METHODS This paper discusses the mechanism of action, uroselectivity and clinical efficacy/tolerability of Silodosin. Additionally, drug interactions and urodynamic effects are reviewed with a focus on ejaculatory dysfunction. CONCLUSIONS Silodosin is a rapidly efficacious and safe agent in the treatment of LUTS/BPH in men. A lack of clinically important cardiovascular side effects makes it of potential use in the elderly. There is a higher risk of ejaculatory dysfunction, which may lead to discontinuation in younger men. The availability of generic counterparts may make this compound less marketable in countries with social healthcare systems.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D058668 Adrenergic alpha-1 Receptor Antagonists Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. Adrenergic alpha-1 Antagonists,Adrenergic alpha-1 Receptor Blockers,Adrenergic alpha1-Antagonists,alpha-1 Adrenergic Blocking Agents,alpha1-Adrenergic Antagonists,alpha1-Adrenoceptor Blocker,Adrenergic alpha 1 Antagonists,Adrenergic alpha 1 Receptor Antagonists,Adrenergic alpha 1 Receptor Blockers,Adrenergic alpha1 Antagonists,Antagonists, alpha1-Adrenergic,alpha 1 Adrenergic Blocking Agents,alpha-1 Antagonists, Adrenergic,alpha1 Adrenergic Antagonists,alpha1 Adrenoceptor Blocker,alpha1-Antagonists, Adrenergic
D059411 Lower Urinary Tract Symptoms Symptoms of disorders of the lower urinary tract including frequency, NOCTURIA; urgency, incomplete voiding, and URINARY INCONTINENCE. They are often associated with OVERACTIVE BLADDER; URINARY INCOMPETENCE; and INTERSTITIAL CYSTITIS. Lower urinary tract symptoms in males were traditionally called PROSTATISM. Lower Urinary Tract Symptom
D060735 Pharmacovigilance The detection of long and short term side effects of conventional and traditional medicines through research, data mining, monitoring, and evaluation of healthcare information obtained from healthcare providers and patients. Pharmacovigilances
D018340 Receptors, Adrenergic, alpha-1 A subclass of alpha-adrenergic receptors that mediate contraction of SMOOTH MUSCLE in a variety of tissues such as ARTERIOLES; VEINS; and the UTERUS. They are usually found on postsynaptic membranes and signal through GQ-G11 G-PROTEINS. Adrenergic alpha-1 Receptors,Receptors, alpha-1 Adrenergic,alpha-1 Adrenergic Receptors,Adrenergic Receptor, alpha-1,Adrenergic alpha-1A Receptors,Adrenergic alpha-1B Receptors,Adrenergic alpha-1D Receptors,Receptor, Adrenergic, alpha-1,Receptor, Adrenergic, alpha-1A,Receptor, Adrenergic, alpha-1B,Receptor, Adrenergic, alpha-1D,Receptors, Adrenergic, alpha-1A,Receptors, Adrenergic, alpha-1B,Receptors, Adrenergic, alpha-1D,alpha 1 Adrenergic Receptor,alpha-1A Adrenergic Receptor,alpha-1B Adrenergic Receptor,alpha-1C Adrenergic Receptor,alpha-1D Adrenergic Receptor,Adrenergic Receptor, alpha 1,Adrenergic Receptor, alpha-1A,Adrenergic Receptor, alpha-1B,Adrenergic Receptor, alpha-1C,Adrenergic Receptor, alpha-1D,Adrenergic Receptors, alpha-1,Adrenergic alpha 1 Receptors,Adrenergic alpha 1A Receptors,Adrenergic alpha 1B Receptors,Adrenergic alpha 1D Receptors,Receptor, alpha-1 Adrenergic,Receptor, alpha-1A Adrenergic,Receptor, alpha-1B Adrenergic,Receptor, alpha-1C Adrenergic,Receptor, alpha-1D Adrenergic,Receptors, Adrenergic alpha-1,Receptors, Adrenergic alpha-1A,Receptors, Adrenergic alpha-1B,Receptors, Adrenergic alpha-1D,Receptors, alpha 1 Adrenergic,alpha 1 Adrenergic Receptors,alpha 1A Adrenergic Receptor,alpha 1B Adrenergic Receptor,alpha 1C Adrenergic Receptor,alpha 1D Adrenergic Receptor,alpha-1 Adrenergic Receptor,alpha-1 Receptors, Adrenergic,alpha-1A Receptors, Adrenergic,alpha-1B Receptors, Adrenergic,alpha-1D Receptors, Adrenergic

Related Publications

Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
November 2017, The Cochrane database of systematic reviews,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
October 2008, International journal of urology : official journal of the Japanese Urological Association,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
June 2011, Hinyokika kiyo. Acta urologica Japonica,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
April 2007, Indian journal of urology : IJU : journal of the Urological Society of India,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
December 2007, Expert opinion on investigational drugs,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
September 2017, Lower urinary tract symptoms,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
June 2019, Urologiia (Moscow, Russia : 1999),
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
April 2010, Neurourology and urodynamics,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
August 2000, Prostate cancer and prostatic diseases,
Nadir I Osman, and Christopher R Chapple, and Francisco Cruz, and François Desgrandchamps, and Carlos Llorente, and Francesco Montorsi
August 2016, The Urologic clinics of North America,
Copied contents to your clipboard!